Cefotetan: antibacterial activity against Staphylococcus aureus in the presence of human serum.
Cefotetan is a broad spectrum cephamycin antibiotic with a long serum half-life (3-4.5 h): this is explained, in part, by serum-protein-binding (SPB) of 88%. The rate of kill of Staphylococcus aureus by cefotetan was assessed in human serum or broth containing reducing concentrations of drug simulating those seen following a 1 g intravenous dose to man. Cefotetan was bactericidal in serum despite the assumed concentration of unbound drug never reaching the minimum inhibitory concentration (MIC) for the test strain. In a separate study, ceftriaxone (SPB 96%) was more active in broth (MIC 4 mg/1) than cefotetan (MIC 16 mg/1). In 100% serum the minimum bactericidal concentration (MBC) of ceftriaxone was 64 mg/1 whilst the MBC for cefotetan was 16 mg/1.
Edwards
J R
JR
Antibiotic Development, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, England.
D001798:Blood Proteins / Q000378:metabolism; D015313:Cefotetan / Q000097:blood / Q000494:pharmacology*; D002443:Ceftriaxone / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D013211:Staphylococcus aureus / Q000187:drug effects*
D001798:Blood Proteins; D015313:Cefotetan; D002443:Ceftriaxone